ArticleCancer2021
Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.
Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.The oncologist · 2025Pooled it
- Implementation of a clinical trial communication skills training workshop for oncology fellows: A mixed methods evaluation.PEC innovation · 2026Article
- Trends in Breast and Axillary Operations in Young Patients with Operable Breast Cancer from the National Cancer Database (NCDB): De-escalation of Axillary Surgery and Increased Use of Radiation.Annals of surgical oncology · 2026Article
- Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.Annals of surgical oncology · 2026Article
- Definition of Sporadic Early-Onset Invasive Solid Organ Cancers in Adults.Oncology and therapy · 2026Article
- Clinical Characteristics and Outcomes of Acute Mesenteric Ischemia in Young Adults: A KASID Multicenter Study.Gut and liver · 2025Article
- New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials.Blood advances · 2025Review
- Insights From Diverse Perspectives on Social Media Messages to Inform Young Adults With Cancer About Clinical Trials: Focus Group Study.JMIR formative research · 2025Article
- Closing the gap: proposing a socio-ecological framework to make cancer clinical trials more accessible, equitable, and acceptable to adolescents and young adults.The oncologist · 2024Article
- Strategies for increasing accrual in cancer clinical trials: What is the evidence?Cancer medicine · 2024Review
- Exclusion of pregnant and lactating persons from breast cancer clinical trials: a review of active trials registered on ClinicalTrials.gov.Acta obstetricia et gynecologica Scandinavica · 2024Review
- Article
- Access to Care for Adolescents and Young Adults With Cancer in the United States: State of the Literature.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Long-term oncologic outcomes following breast cancer surgery in adolescents and young adults: a single-center retrospective analysis.Frontiers in oncology · 2024Article
- Article
- Clinicopathological characteristics and prognosis of adolescents and young adults with gastric cancer after gastrectomy: a propensity score matching analysis.Frontiers in oncology · 2023Article
- Article
- Challenges of Systemic Therapy Investigations for Bone Sarcomas.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAdolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival as younger (pediatric) patients and older patients (adults 40 years old or older). This may be related to their lower participation in clinical trials.
methodsThis study examined AYA patient accrual to SWOG Cancer Research Network phase 1 to 3 clinical treatment trials for 29 cancers over 25 years (January 1996 to December 2020). Trial enrollments for AYA patients (15-39 years old) were compared with trial enrollments for older patients (40 years old or older) in SWOG and with US AYA cancer population rates derived from US Census and National Cancer Institute/Surveillance, Epidemiology, and End Results data.
resultsIn total, 84,219 patients were enrolled in SWOG treatment trials, including 7109 AYA patients (8.4%); in contrast, AYAs constituted 3.8% of the US cancer population. By histology, the highest proportions of AYA patients were in trials for Hodgkin disease (825 of 1220; 67.6%) and acute lymphocytic leukemia (350 of 678; 51.6%), whereas breast cancer trials had the greatest number of AYA patients (3032 of 32,693; 9.3%). SWOG AYA patients were more often female (68.8% vs 58.7%; P < .001), Black (10.1% vs 8.2%; P < .001), and Hispanic (10.6% vs 5.6%; P < .001) than SWOG patients who were 40 years old or older, and they were more often female (68.8% vs 65.1%; P < .001) but less often Black (10.1% vs 11.8%; P < .001) or Hispanic (10.6% vs 12.8%; P < .001) than AYA patients in the US cancer population.
conclusionsAYA patients with cancer were well represented in SWOG clinical trials in comparison with US cancer population patients with the same cancers. The SWOG AYA population was more racially/ethnically diverse than older SWOG patients, although it was less diverse than the US AYA cancer population. LAY SUMMARY: Adolescent and young adult (AYA) patients with cancer (aged 15-39 years) have not seen the same improvements in survival as younger (pediatric) patients and older patients (adults 40 years old or older). This may be related to their lower participation in clinical trials. This study evaluated the extent to which AYA patients were enrolled in a large, National Cancer Institute-sponsored network group over 25 years (1996-2020). Overall, 8.4% of the enrolled patients (7109 of 84,219) were AYAs; this was twice the corresponding rate of 3.8% in the US cancer population. AYA patients were also more racially/ethnically diverse than older trial patients, although they were less racially/ethnically diverse than the US AYA cancer population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.